|
Delayed
NSE India S.E.
04:36:38 01/09/26 pm AEST
|
5-day change | 1st Jan Change | ||
| 1,939.40 INR | -2.29% |
|
+1.53% | +12.76% |
| 01/09 | Trump announces new round of drug-pricing deals | RE |
| 05/08 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| Market Cap | 4,762B 50.05B 43.09B 40.46B 36.94B 69.39B 69.88B 479B 187B 2,415B 188B 184B 7,996B | P/E 2027 * |
36.6x | P/E 2028 * | 31x |
|---|---|---|---|---|---|
| Enterprise Value | 4,492B 47.21B 40.64B 38.16B 34.84B 65.44B 65.91B 452B 176B 2,278B 177B 173B 7,541B | EV / Sales 2027 * |
6.9x | EV / Sales 2028 * | 6.07x |
| Free-Float |
44.39% | Yield 2027 * |
0.86% | Yield 2028 * | 1% |
Last Transcript : Sun Pharmaceutical Industries Ltd.
| 1 day | -2.30% | ||
| 1 week | +1.53% | ||
| Current month | -2.58% | ||
| 1 month | -2.58% | ||
| 3 months | +7.94% | ||
| 6 months | +10.78% | ||
| Current year | +12.76% |
| 1 week | 1,896.2 |  | 1,984.8 |
| 1 month | 1,868.3 | | 1,988 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.29% | +1.53% | +24.05% | +74.45% | 50.05B | |
| +1.14% | +1.47% | +56.16% | +123.40% | 40.29B | |
| +0.20% | +5.45% | +17.45% | +85.99% | 12.17B | |
| +0.12% | -1.85% | -11.08% | +12.22% | 11.96B | |
| +0.19% | -.--% | +29.35% | +150.00% | 9.25B | |
| -1.80% | -1.50% | +25.41% | +48.78% | 7.62B | |
| +0.32% | +4.07% | +29.13% | +224.46% | 7.36B | |
| +1.43% | +1.70% | +45.95% | -9.99% | 7.21B | |
| -0.84% | -2.36% | -36.62% | +16.04% | 5.26B | |
| -1.62% | -1.02% | +44.51% | +105.12% | 4.73B | |
| Average | -0.31% | +1.06% | +22.43% | +83.05% | 15.59B | |
| Weighted average by Cap. | -0.49% | +1.73% | +29.34% | +88.59% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.84B 5.89B 5.53B 5.05B 9.49B 9.55B 65.55B 25.5B 330B 25.69B 25.13B 1,093B | 729B 7.66B 6.6B 6.19B 5.65B 10.62B 10.7B 73.4B 28.56B 370B 28.77B 28.14B 1,224B |
| Net income | 130B 1.36B 1.17B 1.1B 1.01B 1.89B 1.9B 13.05B 5.08B 65.75B 5.12B 5.01B 218B | 154B 1.61B 1.39B 1.31B 1.19B 2.24B 2.25B 15.47B 6.02B 77.91B 6.06B 5.93B 258B |
| Net Debt | -271B -2.84B -2.45B -2.3B -2.1B -3.94B -3.97B -27.25B -10.6B -137B -10.68B -10.45B -454B | -338B -3.56B -3.06B -2.88B -2.62B -4.93B -4.97B -34.07B -13.26B -172B -13.35B -13.06B -568B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/09/26 | INR 1,939.40 | -2.29% | 1,294,455 |
| 31/08/26 | INR 1,984.80 | +3.37% | 2,413,221 |
| 28/08/26 | INR 1,920.00 | +0.35% | 1,140,742 |
| 27/08/26 | INR 1,913.30 | +0.73% | 1,107,552 |
| 26/08/26 | INR 1,899.50 | -1.17% | 648,845 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
